TrialBMC infectious diseases2026

SHIELD study: a multicenter, open-label, single-arm trial to evaluate the safety, pharmacokinetics and antiviral activity of fostemsavir in combination with optimized background therapy (OBT) in children and adolescents with HIV who are failing their current combination antiretroviral therapy (cART) and have dual- or triple-class antiretroviral (ARV) resistance.

Carlos Grasa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.